| scholarly article | Q13442814 |
| P2093 | author name string | Manabu Suzuki | |
| Katsuhiro Harada | |||
| Yasuyo Suga | |||
| Yoshihiro Morinaga | |||
| Sumiko Ehara | |||
| Yukio Nihei | |||
| P2860 | cites work | Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. | Q33879273 |
| Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product. | Q34167120 | ||
| Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections | Q36135626 | ||
| In vitro antagonism between cisplatin and vinca alkaloids | Q42049686 | ||
| Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. | Q42203168 | ||
| Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy | Q43956053 | ||
| Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma | Q43979874 | ||
| Vinca alkaloids: anti-vascular effects in a murine tumour | Q46555781 | ||
| Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships | Q47762267 | ||
| A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. | Q55241476 | ||
| P433 | issue | 2 | |
| P921 | main subject | cisplatin | Q412415 |
| P304 | page(s) | 200-204 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo | |
| P478 | volume | 94 |
| Q92704134 | Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review |
| Q55131866 | Drug-induced amplification of nanoparticle targeting to tumors. |
| Q38836161 | Early investigational tubulin inhibitors as novel cancer therapeutics |
| Q80414598 | In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine |
| Q34013517 | In vivo growth-inhibition of Sarcoma 180 by an alpha-(1-->4)-glucan-beta-(1-->6)-glucan-protein complex polysaccharide obtained from Agaricus blazei Murill. |
| Q37534993 | Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies |
| Q33421897 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q52650797 | Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. |
| Q37716872 | Phase III Soft Tissue Sarcoma Trials: Success or Failure? |
| Q33729945 | Serum immunoglobulin fused interferon-alpha inhibited tumor growth in athymic mice bearing colon 26 adenocarcinoma cells |
| Q26781365 | Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? |
| Q40244679 | Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors |
| Q37528662 | The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma |
| Q34122191 | The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents |
| Q52627703 | The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. |
| Q52659096 | Tumour vascular-disrupting agents in soft-tissue sarcoma. |
Search more.